Medicenna Therapeutics Corp.
TSX Exchange | Jul 14, 2020, 12:04 PM EDT | Real-time price
-0.01 (-0.20%)
14,146
(1) Number based only on listed classes of shares.
(2) Number sourced from third party data provider. For the most up to date information, please refer to the company's financial documents.
*Market Capitalization is based on Total Shares Outstanding for all share classes for the company. Convertible bonds and employee stock options that would otherwise be included in the Diluted Shares amount included in a company's filings/financials are not included.
Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines (IL4-ECs) that specifically target the Interleukin-4 Receptor (IL4R) which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The IL4-ECs have the po... More
Medicenna to Present at Raymond James Human Healthcare Innovation Conference
PR Newswire , 7:00 AM EDT June 11, 2020
Medicenna to Present at Raymond James Human Healthcare Innovation Conference
Canada Newswire , 7:00 AM EDT June 11, 2020
47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th
ACCESSWIRE , 9:00 AM EDT June 03, 2020
Medicenna to Present at Raymond James Human Healthcare Innovation Conference
PR Newswire , 7:00 AM EDT June 11, 2020
Medicenna to Present at Raymond James Human Healthcare Innovation Conference
Canada Newswire , 7:00 AM EDT June 11, 2020
47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th
ACCESSWIRE , 9:00 AM EDT June 03, 2020
